Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2024-07-03 Board/Management Inform…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
PTX appoints Dr Gavin Shepherd as Non-Executive Director 3 pages 195.4KB
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new Non-Executive Director, Dr Gavin Shepherd, to the Board of Prescient Therapeutics Limited. It provides biographical details, the effective date of appointment, and statements from the Chair and the appointee. There is no financial data, no discussion of financial results, no regulatory filings, no voting results, and no mention of any report publication. The content focuses solely on management/board changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is detailed about the appointment, confirming it is not a brief notice or a report publication announcement.
2024-07-03 English
Change of Director's Interest Notice 2 pages 182.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of securities held before and after the change, nature of the change, and dates. The document is short (3686 characters) and focuses solely on insider share transactions by a director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). There is no indication of financial results, management discussion, or other report types. Therefore, the correct classification is DIRS.
2024-06-03 English
Notification of cessation of securities - PTX 4 pages 14.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Prescient Therapeutics Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's issued securities, specifically the cessation of options due to expiry without exercise or conversion. This type of announcement fits the category of Share Issue/Capital Change (SHA), as it relates to changes in the company's capital structure through cessation of securities. The document length is 4226 characters, which is consistent with a detailed announcement rather than a brief notice or a full financial report. Therefore, the appropriate classification is SHA.
2024-06-03 English
PTX invited to present at international lymphoma forum 4 pages 257.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Prescient Therapeutics will present clinical trial results (PTX-100 Phase 1b) at an upcoming medical conference (the 15th Annual T-Cell Lymphoma Forum). It discusses clinical trial progress, future plans for Phase 2 trials, and provides background on the company and its therapies. There are no financial statements, regulatory filings, voting results, or detailed financial data. The document is an announcement of a presentation of clinical data rather than the presentation itself or a formal report. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing or legal proceeding update. The content fits best as a general regulatory announcement about company activities and upcoming presentations, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2024-05-19 English
March 2024 Quarterly Update and Appendix 4C 10 pages 501.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'March 2024 Activities Report and Appendix 4C' and includes detailed quarterly cash flow statements and an activities report for the March 2024 quarter. It provides financial summaries, operational updates, clinical trial progress, and cash flow data. The presence of the Appendix 4C quarterly cash flow statement, which is a regulatory requirement for Australian listed entities, indicates this is a quarterly report. The document contains substantive financial data and analysis, not just an announcement or a brief summary. It is not an annual report, earnings release, or a simple announcement of report publication. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-04-29 English
PTX100 Ph1b results to be presented at specialist congress 4 pages 264.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the results of a Phase 1b clinical trial of PTX-100 in T-cell lymphomas will be presented at a specialist cancer congress (the 5th World Congress of Cutaneous Lymphomas). It includes details about the clinical trial, the drug candidates, and the upcoming presentation event. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of clinical trial results presentation rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement about clinical trial progress and upcoming presentation, which is best classified as a Regulatory Filing (RNS) since it is a general announcement that does not fit other specific categories.
2024-04-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.